Pioglitazone prevents cardiac remodeling in high-fat, high-calorie-induced Type 2 diabetes mellitus

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 291, Issue 1, 2006, Pages

  Rodriguez, Walter E ^a   Joshua, Irving G ^a   Falcone, Jeff C ^a   Tyagi, Suresh C ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Acetylcholine; Cardiac rings; Endothelial myocyte coupling; Heart failure; Homocysteine; Matrix metalloproteinase; Nitric oxide; Nitroprusside; Peroxisome proliferator

Indexed keywords

GELATINASE B; HOMOCYSTEINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALORIC INTAKE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; ECHOCARDIOGRAPHY; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE CONTRACTION; HEART MUSCLE; LIPID DIET; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; ZYMOGRAPHY;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIETARY FATS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENERGY INTAKE; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED C57BL; PPAR GAMMA; THIAZOLIDINEDIONES; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 33745712694     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01331.2005     Document Type: Article

References (34)

1. Abdelrahman M, Sivarajah A, and Thiemermann C. Beneficial effects of PPAR-gamma ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc Res 65: 772-781, 2005.
2. Bar-On H, Kidron M, Friedlander Y, Ben-Yehuda A, Selhub J, Rosenburg IH, and Friedman G. Plasma total homocysteine levels in subjects with hyperinsulinemia. J Intern Med 247: 287-294, 2000.
3. Buysschaert M, Dramais AS, Wallemacq PE, and Hermans MP. Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care 23: 1816-1822, 2000.
4. Camp TM, Tyagi SC, Senior RM, Hayden MR, and Tyagi SC. Gelatinase B (MMP-9) an apoptotic factor in diabetic transgenic mice. Diabetologia 46: 1438-1445, 2003.
5. Carroll JF and Tyagi SC. Extracellular matrix remodeling in heart of homocysteinemic obese rabbit. Am J Hypertens 18: 692-698, 2005.
6. Cox MJ, Sood HS, Hunt MJ, Chandler D, Henegar JR, Aru GM, and Tyagi SC. Apoptosis in the left ventricle of chronic volume overload causes endocardial endothelial dysfunction in rats. Am J Physiol Heart Circ Physiol 282: H1197-H1205, 2002.
7. Death AK, Fisher EJ, McGrath KC, and Yue DK. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis 168: 263-269, 2003.
8. Evans M, Anderson RA, Graham J, Ellis GR, Morris K, Davies S, Jackson SK, Lewis MJ, Frenneaux MP, and Rees A. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation 101: 1773-1779, 2000.
9. Hao F and Yu JD. High glucose enhance expression of matrix metalloproteinase-2 in smooth muscle cells. Acta Pharmacol Sin 24: 534-538, 2003.
10. Hoogeveen EK, Kostense PJ, Jakobs C, Dekker JM, Nijpels G, Heine RJ, Bouter LM, and Stehouwer CD. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Circulation 101: 1506-1511, 2000.
11. Horio T, Suzuki M, Suzuki K, Takamisawa I, Hiuge A, Kamide K, Takiuchi S, Iwashima Y, Kihara S, Funahashi T, Yoshimasa Y, and Kawano Y. Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. Am J Hypertens 18: 949-957, 2005.
12. Hunt MJ, Aru GM, Hayden MR, Moore CK, Hoit BD, and Tyagi SC. Induction of oxidative stress and disintegrin metalloproteinase in human heart end-stage failure. Am J Physiol Lung Cell Mol Physiol 283: L239-L245, 2002.
13. Kanie N, Matsumoto T, Kobayashi T, and Kamata K. Relationship between peroxisome proliferator-activated receptors (PPARα and γ) and endothelium-dependent relaxation in streptozoticin-induced diabetic rats. Br J Pharmacol 140: 23-32, 2003.
14. Marx N. PPARgamma and vascular inflammation: adding another piece to the puzzle. Circ Res 91: 373-374, 2002.
15. Miller A, Mujumdar V, Palmer L, Bower JD, and Tyagi SC. Reversal of endocardial endothelial dysfunction by folic acid in homocysteinemic hypertensive rats. Am J Hypertens 15: 157-163, 2002.
16. Moshal KS, Tyagi N, Henderson B, Ovechkin AV, and Tyagi SC. Protease activated receptor and endothelial-myocyte uncoupling in chronic heart failure. Am J Physiol Heart Circ Physiol 288: H2770-H2777, 2005.
17. Mujumdar VS, Smiley LM, and Tyagi SC. Activation of matrix metalloproteinase dilates and decreases cardiac tensile strength. Int J Cardiol 79: 277-286, 2001.
18. Murthy SN, Obregon DF, Chattergoon NN, Fonseca NA, Mondal D, Dunne JB, Diez JG, Jeter JR Jr, Kadowitz PJ, Agrawal KC, McNamara DB, and Fonseca VA. Rosiglitazone reduces serum homocysteine levels, smooth muscle proliferation and intimal hyperplasia in Sprague-Dawley rats fed a high methionine diet. Metabolism 54: 645-652, 2005.
19. Nishimoto Y, Tomida T, Matsui H, Ito T, and Okaumura K. Decrease in renal medullary eNOS of fructose-fed, salt-sensitive hypertensive rats. Hypertension 40: 190-194, 2002.
20. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, and Milburn M. Ligand binding and co-activator assembly of the PPARα. Nature 395: 137-143, 1998.
21. Papaioannou VE and Fox JG. Efficacy of tribromoethanol anesthesia in mice. Lab Anim Sci 43: 189-192, 1993.
22. Parekh PI, Petro AE, Tiller JM, Feinglos MN, and Surwit RS. Reversal of diet-induced obesity and diabetes in C57BL/6J mice. Metabolism 47: 1089-1096, 1998.
23. Petro AE, Cotter J, Cooper DA, Peters JR, Surwit SJ, and Surwit RS. Fat, carbohydrate, and calories in the development of diabetes and obesity in the C57BL/6J mouse. Metabolism 53: 454-457, 2004.
24. Pouwels MJ, den Heijer M, Blom HJ, Tack CJ, and Hermus AR. Improved insulin sensitivity and metabolic control in type 2 diabetes does not influence plasma homocysteine. Diabetes Care 26: 1637-1639, 2003.
25. Roberts JT and Wearn JT. Quantitative changes in the capillary-muscle relationship in human hearts during normal growth and hypertrophy. Am Heart J: 617-633, 1941.
26. Schulze MB and Hu FB. Primary prevention of diabetes: what can be done and how much can be prevented? Annu Rev Public Health 26: 445-467, 2005.
27. Shukla N, Thompson CS, Angelini GD, Mikhailidis DP, and Jeremy JY. Homocysteine enhances impairment of endothelium dependent relaxation and cGMP formation in aortae from diabetic rabbits. Diabetologia 45: 1325-1331, 2002.
28. Smiley LM, Camp TM, Lucchesi PA, and Tyagi SC. Peroxisome proliferator ameliorates endocardial endothelial and muscarinic dysfunction in spontaneously hypertensive rats. Antioxid Redox Signal 6: 367-374, 2004.
29. Surwit RS, Feinglos MN, Rodin J, Sutherland A, Petro AE, Opara EC, Kuhn CM, and Rebuffe-Scrive M. Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. Metabolism 44: 645-651, 1995.
30. Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, and Feinglos MN. Diet-induced type II diabetes in C57BL/6J mice. Diabetes 9: 1163-1167, 1988.
31. Tarone RE. A modified Bonferroni method for discrete data. Biometrics 46: 515-522, 1990.
32. Tyagi SC, Smiley LM, and Mujumdar VS. Homocyst(e)ine impairs endocardial endothelial function. Can J Physiol Pharmacol 77: 950-957, 1999.
33. Tyagi SC, Smiley LM, Mujumdar VS, Clonts B, and Parker JL. Reduction-oxidation (redox) and vascular tissue level of homocyst(e)ine in human coronary atherosclerotic lesions and role in vascular ECM remodeling and vascular tone. Mol Cell Biochem 181: 107-116, 1998.
34. Yamamoto K, Ohki R, Lee RT, Ikeda U, and Shimada K. Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiomyocytes. Circulation 104: 1670-1675, 2001.